Gene Therapy for Hearing Loss: FDA Approves First-Ever Deafness Cure in 2026

# Gene Therapy for Hearing Loss: FDA Approves First-Ever Deafness Cure in 2026

> **Quick answer:** The FDA approved Otarmeni (lunsotogene parvec-cwha) on April 23, 2026 — the world's first gene therapy for inherited deafness caused by OTOF gene mutations. A landmark study in *Nature*, published the same week by Harvard Medical School and Mass Eye and Ear researchers, found that 90% of patients regained meaningful hearing after a single injection, with half reaching normal hearing levels within 2.5 years. Regeneron Pharmaceuticals will provide the drug free of charge to U.S. patients. This is a turning point in the history of medicine.

Gene therapy for hearing loss has moved from science fiction to FDA-approved reality. In the span of 48 hours last week, two events reshaped what it means to be born deaf: a landmark *Nature* study confirmed that 90% of participants recovered meaningful hearing after a single cochlear injection, and the FDA granted approval for the first-ever gene therapy for inherited deafness. For families who have spent years navigating the world of cochlear implants, speech therapy, and audiology assessments, this is not just a medical milestone — it is a profoundly personal one.

This article is for informational purposes only and does not replace professional medical advice. Consult a healthcare provider for medical concerns.

## What the FDA Just Approved — and Why It Matters

On April 23, 2026, the U.S. Food and Drug Administration approved **Otarmeni** (lunsotogene parvec-cwha), developed by Regeneron Pharmaceuticals, making it the first approved gene therapy in history to restore a neurosensory function to normal levels. The approval was granted under the National Priority Voucher Program, reflecting the therapy's breakthrough designation status.